AstraZeneca inks $1.5B license deal for lung cancer drug
AstraZeneca (AZN) will pay China's Dizal Jiangsu Pharmaceutical $600M upfront for global rights to a lung cancer drug, strengthening its oncology portfolio with a commercial-stage treatment.
The drugmaker has entered into an exclusive license deal with Dizal for Zegfrovy (sunvozertinib), a novel
How it works
Once you click Generate, Ollama reads this article and crafts 5 comprehension questions. Your answers are graded against the article content — general knowledge won't be enough. Score 70+ to count toward your certificate.
Questions are cached — you'll always get the same 5 for this article.